Laserfiche WebLink
CCV Ernei-gency Response Plan <br /> NORTH <br /> 5.14.26 Caustic Soda: (50% NaOH): Used as a pH modifier, primarily as initial dilutant of sodium <br /> cyanide. <br /> 5.14.27 Response Procedure: <br /> (a) Personnel shall wear full protective clothing/gear. <br /> (b) SCBA's or chemical goggles and face shield should be used to protect the face. <br /> (c) If the spill has breached a concrete containment, control with soil berms. <br /> (d) Dilute spill with water <br /> 5.14.28 Hydrogen Peroxide: <br /> Hydrogen Peroxide is used to manufacture the CAROs acid used to detoxify cyanide in tailings <br /> and is located at the Warehouse Facility <br /> 5.14.29 Response Procedure: <br /> (a) Personnel shall wear full protective clothing/gear. <br /> (b) SCBA's or chemical goggles and face shield should be used to protect the face. <br /> (c) If the spill has breached a concrete containment, control with soil berms. <br /> (d) Small spill flood with water to dilute and neutralize spill. <br /> (e) Large spill absorb with dry earth, sand or other non-combustible material. <br /> (f) Although diluted, neutralized hydrogen peroxide has converted to water, the solution should <br /> be returned to the process circuit as a best management practice. <br /> 5.14.30 Teller County Emergency Medical Services Protocol <br /> 5.14.30.1 Hydroxycobalamin (Cyanokit) Administration: <br /> Only authorized Mine Rescue Team Member or Teller County EMS can administer this <br /> drug. <br /> 5.14.30.2 Indications: <br /> Treatment of known or suspected cyanide toxicity /exposure. <br /> (a) Common symptoms: headache, confusion, dyspnea, chest tightness, and nausea. <br /> (b) Common signs: AMS, seizures, coma, mydriasis, tachypnea (early), apnea (late), <br /> (c) Hypertension (early), hypotension (late), cardiovascular collapse, vomiting, and <br /> (d) Elevated lactate. <br /> 5.14.30.3 Precautions: <br /> (a) Caution in patients with history of anaphylactic reactions to hydroxycobalamin or <br /> cyanocobalamin, but consider administration if life threatening cyanide toxicity. <br /> (b) No pediatric doses are known for the United States, but non-US areas have used a dose of <br /> 70mg/kg IV for treatment of pediatric patients. <br /> 5.14.30.4 Adverse Reactions: <br /> (a) Substantial increases in blood pressure may occur follow administration. <br /> (b) Administration should NOT be withheld due to hypertension however; patient will likely have <br /> a change in urine and secretion color as well as skin redness after administration. <br /> (c) Co-oximetry including carboxyhemoglobin levels can be inaccurate after administration due <br /> to the bright red color of the medication. <br /> (d) July 24, 2015 <br /> Department THIS DOCUMENT IS UNCONTROLLED IN HARD COPY FORMAT Doc Id:NA-CCV-HSLP-PLAN-1775 <br /> Health Safety&Loss Prevention Date of This Issue:25 June 2018 Date of Next Review:25 June 2019 Page 24 of 38 <br />